-+ 0.00%
-+ 0.00%
-+ 0.00%

Rothschild & Co Initiates Coverage On Apogee Therapeutics with Buy Rating, Announces Price Target of $140

Benzinga·05/01/2026 11:53:08
Listen to the news
Rothschild & Co analyst Qize Ding initiates coverage on Apogee Therapeutics (NASDAQ:APGE) with a Buy rating and announces Price Target of $140.